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ABSTRACT
Hemozoin, a bio-crystalline substance, is a hemin detoxification by-product of malaria parasites. The role of
hemozoin crystals in host immune system modulation by malaria parasites, and how they interact with the im-
mune system has been enigmatic. Here, we summarize recent progress in our understanding of how hemozoin
might be interacting with the host immune system. In particular, the potential application of hemozoin crystals
as an adjuvant may provide insights into the molecular mechanisms involved in immune responses to malarial
infection and provide a rationale for the design of vaccines against malaria as well as other immunological dis-
orders such as allergies.
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INTRODUCTION
Vaccination has been used effectively for protection
from, and treatment of, not only infectious diseases,
but also non-infectious diseases such as cancer and
allergies. A vaccine is comprised of two components:
an antigen and an adjuvant. Antigens are usually
pathogen-derived and mostly protein nature and suc-
cessful vaccines usually elicit adequate humoral and
or cellular immune responses. An adjuvant is a com-
pound that can either promote, or modulate, vaccine
immunogenicity.1 Without an adjuvant, it is not possi-
ble to induce optimal immune responses, referred to
as the ‘immunologist’s dirty little secret’ by Charles
Janeway Jr.2
Although little is known about how adjuvants work,
every successful vaccine contains an adjuvant,
whether externally introduced, or endogenously
“built-in”. Recent advances in immunology research
have shown that innate immune system receptors
recognize molecular patterns associated with patho-
gens (PAMPs), which are often used as vaccine adju-
vants.3 These receptors are localized in, or on, the
surface of many immune cells as well as non-immune
cells. Toll-like receptors (TLRs) are located on the
cell membrane or in the endosome, whereas RIG-I
like receptors (RLRs) and NOD-like receptors
(NLRs) are expressed in the cytosol. Many ligands,
such as modified lipid-A (the TLR4 ligand), poly-IC
(synthetic dsRNA, the TLR3 ligand), CpG oligode-
oxynucleotides (synthetic ssDNA, the TLR9 ligand),
and peptidoglycan (the NOD-like Receptor ligand),
are known to act as potent adjuvants. These vaccine
adjuvants can directly target antigen presenting cells
(APCs), such as dendritic cells (DCs), thereby lead-
ing to the subsequent triggering of adaptive immune
responses.4
Despite the need for better adjuvants, there are
very few clinically approved adjuvants for human use
(e.g. aluminum salts or monophosphoryl lipid A
[MPL]) due to safety concerns, such as unwanted
side-effects. Because the evaluation of new adjuvants
is both time and energy consuming, basic research
should focus on finding better, safer and more potent
adjuvants for clinical use. In this review article, we fo-
cus on hemozoin, a malarial metabolite, as a novel
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vaccine adjuvant. We discuss how it was found to be
an adjuvant, and its underlying mechanism of action.
We also discuss recent progress in the preclinical de-
velopment of this hemozoin adjuvant for use in an
anti-mite allergy vaccine against canine atopic derma-
titis.
HEMOZOIN: A MALARIAL METABOLITE
Malaria is a disease caused by Plasmodium parasites,
and has a history as old as that of the human race. Ac-
cording to the 2008 report of the World Health Or-
ganization (WHO), half of the world’s population is
still at risk of malaria; in 2006, 250 million cases were
encountered with approximately 1 million deaths
(WHO, World Malaria Report, 2008 at http:apps.
who.intmalariawmr2008). It has been almost 130
years since the microscopic identification of the ma-
laria parasite and its complex life cycle through trans-
mission by the Anopheles mosquito. A dark-brown
pigment called hemozoin was the first noticed in the
Plasmodium-infected blood of both patients and mos-
quitoes.5 As the parasite multiplies in the erythro-
cytes of its vertebrate host, hemozoin is continuously
produced and released together with the merozoites,
and engulfed by macrophages, monocytes, neutro-
phils and other immune cells such as DCs.6 Hemo-
zoin is also carried into mosquitoes through the mos-
quito blood meal, either inside infected erythrocytes,
or in leukocytes, (Fig. 1).7
Hemozoin is a metabolic byproduct of heme mole-
cules, which are digested by the Plasmodium para-
sites. During its life in erythrocytes, the parasite uses
the host-hemoglobin for its vital needs, such as amino
acids and iron in which the free-heme (Fe2+-
protophorphyrin IX) is detoxified by converting it
into insoluble crystals. The conversion process from
heme to hemozoin crystals is thought to be a bio-
crystallization process that takes place in the diges-
tive vacuole of the parasites (pH < 6) residing within
the erythrocytes (Fig. 2).8 The hemozoin bio-crystals
are identical to synthetic β-hematin crystals (sHZ),
which can be chemically synthesized from hemin
chloride under acidic conditions. β-hematin crystals
are composed of cyclic heme dimers integrated into
each other through hydrogen bonds in which the
dimeric heme consists of two heme molecules cova-
lently linked through a reciprocal ferric iron (Fe3+)
(Fig. 2b).9 Both synthetic (β-hematin) and natural
hemozoin crystals have a brick-like shape, with ap-
proximate sizes of 50-500 nm (Fig. 2a, 2c). They also
have similar infrared spectra and X-ray powder dif-
fraction patterns.10,11 It should be noted, however,
that the purification protocols (possibly using differ-
ent solvents and temperatures) used to synthesize β-
hematin crystals under laboratory conditions can af-
fect the size, shape and faces of the crystals (Table
1).10,12 Not surprisingly, several β-hematin prepara-
tion protocols have been used to make different sizes
and shapes of crystals.13-15 Contrary to popular belief,
this is a very important difference between synthetic
and natural hemozoin; that the size and shapes of
synthesized hemozoin crystals may not be identical,
depending on the purification method (Table 1).
While natural hemozoin is composed of smaller,
evenly distributed crystals between 50-500 nm in size,
β-hematin crystals range from 50 nm to 20 μm (Table
1 and13). Moreover, β-hematin crystals in an aqueous
medium tend to aggregate even within minutes of
vigorous sonication (unpublished observations). This
is an important point to consider as different sized
hemozoin crystals may possess variable immuno-
modulatory properties.
INVOLVEMENT OF THE INNATE IMMUNE
SYSTEM IN RESPONSES TO HEMOZOIN
During the repetitive life cycle of the malaria para-
sites in the blood, hemozoin continuously ruptures
from erythrocytes, together with the merozoites and
other parasite products, and accumulates in the re-
ticuloendothelial system (i.e. macrophages, leuko-
cytes and tissues such as the liver and spleen) (Fig.
1). It has been shown in both mouse and human ma-
laria, that the accumulation of hemozoin in leuko-
cytes and organs such as the spleen, liver or brain is
well correlated with disease severity.16-18 Further-
more, it has been suggested that free hemozoin leads
to the continuous targeting of the host innate im-
mune system, leading to both pro- and anti-
inflammatory responses. Accordingly, hemozoin con-
tinuously activates macrophages and DCs to produce
pro-inflammatory cytokines and chemokines such as
IL6, TNFα, IL12, MCP-1 and IL8, and certain anti-
inflammatory cytokines and chemokines such as IL-
10 and MIF.19 Of note, similar to observations in
mammalian cells, hemozoin was found to induce NO
synthase expression in mosquito tissues and cells via
multiple signaling pathways (Fig. 1).7
Recently, many researchers have analyzed mole-
cules from Plasmodium parasites that may activate
the innate immune system. Both TLR2 and TLR9
have been shown to mediate innate immune system
activation by GPI and hemozoin derived from P. falci-
parum.20-23 Also it was recently suggested that uric
acid is released during malarial infections, presum-
ably activating the innate immune system via NLRs.24
This finding is supported by very recent reports that
have shown that synthetic hemozoin (β-hematin)
crystals directly stimulate both mice bone marrow-
derived macrophages and human monocyte cell lines
through the NLRP3 (also known as NALP3) inflam-
masome complex, leading to caspase-1 activation.25-27
TLR9 OR NLRP3?
Is hemozoin a ligand for TLR9, NLRP3 or both?
Hemozoin purified from P. falciparum (or its syn-
thetic version, β-hematin) has been reported to be a
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Fig. 1 Hemozoin in mammalian host circulation and in blood meal of mosquitoes. Infected female Anopheles 
mosquitoes transmit Plasmodium parasites into a vertebrate host through their bites during a blood meal. The re-
petitive life cycle within the erythrocytes of the mammalian host (erythrocytic blood-stage life cycle of Plasmodi
um) is responsible for the clinical symptoms of malaria, such as fever atacks. Hemozoin is produced during the 
repetitive life cycle of parasites in the erythrocytic blood stage (mostly trophozoites and schizonts). Accumulated 
hemozoin and parasite products are released into the blood stream on erythrocyte rupture and are readily cap-
tured by monocyte/macrophages/APCs and neutrophils and the reticulo endothelium system. Phagocytosis of he-
mozoin by immune cels triggers pro- and anti-inflammatory cytokines and chemokines (TNFα, IL1β, MIP-1, MIP-
2, MCP-1, IL12, IL6, IL8, NO, IL10, and MIF). Some of the merozoites diferentiate into their sexual stages, and 
form both female and male gametocytes, which are central to malaria transmission. Gametocytes (also contain-
ing hemozoin) and many other parasite products are taken up during the mosquito blood-meal and trigger mos-
quito cels to produce NOS. Within 10 days, sporozoites are transfered in the salivary glands of mosquitoes, 
ready to be transmited to humans.
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non-DNA TLR9 ligand.22 It was shown that P.
falciparum-purified hemozoin itself can activate in-
nate immune responses both in vivo and in vitro,
leading to the production of cytokines and chemoki-
nes, and the up-regulation of co-stimulatory mole-
cules in a TLR9-dependent manner.22 Interestingly,
the anti-malarial drug chloroquine abrogates hemo-
zoin-induced cytokine production.22 However, it was
questioned later by Parroche et al. that Plasmodium
DNA, and not hemozoin, is the TLR9 ligand, and that
hemozoin itself is not even immunogenic, but simply
facilitates the entry of Plasmodium DNA into immune
cells to target TLR9.23 This controversial claim was
challenged by many groups who confirmed that pure
hemozoin is an inflammatory molecule.13,15,25-27 Both
Jaramillo et al. and our own group showed very
clearly using agarose gel and SDS-page experiments
that synthetic hemozoin is very pure and does not
contain any DNA or protein contaminants (13,15,22 and
unpublished observations). Furthermore, Jaramillo et
al. elegantly showed that Plasmodium hemozoin,
either while residing in the erythrocytes or after
merozoite release into the bloodstream following
schizont rupture, does not co-localize with Plasmo-
dium DNA.15 However, there is a very likely possibil-
ity that parasite DNA may enter immune cells to-
gether with hemozoin and other parasite proteins,
leading to immunomodulation during the natural in-
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Table 1 Methods used to synthesize synthetic hemozoin 
crystals and their diferent sizes and adjuvant properties.
Adjuvant efectCrystal sizeSynthetic Hemozoin purification methods
High50-200 nm1. Acetic acid method
Medium  2-20 μm
Very low  2-60 μm2. Organic base method
None   <50 nmHemin 
chloride
Control
Fig. 2 Hemozoin formation takes place inside the digestive vacuoles of Plasmodium parasites in erythrocytes. 
Plasmodium parasites, while living in erythrocytes, form a digestive vacuole, an acidic compartment important for 
parasite metabolism and survival. The parasites use host-hemoglobin for their vital needs, such as amino acids 
and iron in which the free-heme (Fe2+-protophorphyrin IX) is detoxified by converting it into insoluble crystals 
caled hemozoin (Fe3+-protophorphyrin IX). (a) SEM picture of purified natural hemozoin from P. falciparum. (b) 
Chemical structure of β-hematin crystals. Crystals are composed of cyclic heme dimers integrated into each other 
through hydrogen bonds to form large crystal structures (modified from Egan10). Dimeric heme consists of two 
heme molecules covalently linked through a central feric iron (Fe3+). (c) SEM picture of synthetic β-hematin crys-
tals purified from ultrapure hemin chloride.
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fection process. In this context, further investigation
is needed to understand how hemozoin interacts with
other parasite components after it is taken up by im-
mune cells. Nevertheless, this does not exclude im-
munostimulation by hemozoin itself, since synthetic
hemozoin itself possesses powerful inflammatory
properties without any contaminant from host or
parasite such as LPS or DNA.
A ligand is defined as a molecule that directly binds
to a receptor with a certain affinity and specificity.
Based on this definition, there are several ways to in-
vestigate ligand-receptor interactions. Circular dicro-
ism (CD) spectrum analysis measures the absorption
of circularly polarized light resulting from structural
asymmetry, and is one of the most sensitive ways to
study conformational changes in proteins. This strat-
egy was used by Latz et al., who showed that a re-
combinant TLR9 protein changed its conformation
upon ligation by CpG DNA, i.e. a canonical TLR9
ligand.28 We successfully reproduced their data and
further investigated whether TLR9, and its non-DNA
ligand hemozoin, directly interacted.13 Remarkable
changes in the CD spectra of the TLR9 protein were
Hemozoin Is an Adjuvant from Malaria Parasites
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Fig. 3 Proposed models for innate immune system recognition of natural and synthetic hemozoin. While natural 
hemozoin is recognized extensively by TLR9, innate immune system recognition of synthetic hemozoin might be 
diferent. Synthetic hemozoin crystals may activate the NLRP3 inflammasome, although the mechanism is stil 
not clear. One possibility is that uric acid might be induced by sHZ, and that uric acid is the ligand for NLRP3. An-
other possibility is the involvement of cathepsin B-related lysosomal destabilization. In addition, sHZ may activate 
the Syk/Lyn-kinase-mediated intracelular signaling pathway upstream of NLRP3 or ASC, indicating indirect acti-
vation of NLRP3 and the existence of other hemozoin receptor(s). Moreover, PI3-kinases downstream of Syk, 
may also be involved in the regulation of hemozoin-induced IL1β production.
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observed not only with CpG DNA, but also with syn-
thetic hemozoin (β-hematin) crystals, whereas none
were seen with dsRNA or monosodium urate (MSU)
crystals.13 We also analyzed the nature of the interac-
tion between TLR9 and hemozoin using short pep-
tides containing unique sequences of the TLR9 extra-
cellular domain. Using this approach, several unique
CysXXCys, or Cys motifs, were identified that are re-
sponsible for binding TLR9 to CpG DNA, as well as
hemin (the single unit of hemozoin).13 The direct in-
teraction of these TLR9 motifs with CpG DNA, or
hemozoin were of similar affinity, but their mode of
binding was quite distinct at the atomic level (con-
firmed by NMR titration). These in vitro receptor-
ligand binding studies suggest that hemozoin binds
to a recombinant TLR9 protein with a certain affinity
and specificity, thus fulfilling the definition of a
ligand. It will be of interest to see if a single (or
dimeric) TLR9 molecule can recognize these distinct
ligands based on their structure as well as their
chemistry. This may be clarified using more detailed
methods such as crystal structural analysis.29
It has recently been shown that particulated nano-
molecules, such as aluminum hydroxyl gel and MSU,
asbestos or silica are recognized by NLRP3, and form
large cytosolic complexes known as inflamma-
somes.30,31 Inflammasomes lead to the proteolytic ac-
tivation of pro-inflammatory cytokines such as IL-1β
and IL-18.32 Similarly, recent reports have suggested
that the immune recognition of, and inflammatory re-
sponse to (IL-1β secretion), sHZ is mediated by
NLRP3 in vitro.25-27,33 Although all these reports
show that IL-1β production by macrophages in re-
sponse to sHZ was reduced in mice lacking NLRP3,
the precise mechanism of NLRP3-inflammasome acti-
vation by hemozoin is still unclear (Fig. 3).
It has been proposed that activation of the NLRP3
inflammasome is not due to specific ligation, but
might occur via indirect NLRP3 activation by interme-
diary ATP molecules, or uric acid crystals, released
from damaged cells.34 In support of this idea, Griffith
et al. suggested that uric acid is induced by sHZ, and
Coban C et al.
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that uric acid is a NLRP3 ligand.27 However, Dostert
et al. completely disagree with the idea that uric acid
or ATP are involved in NLRP3 activation by sHZ, and
suggest that NLRP3 activation by sHZ is through
ROS production and potassium efflux, similar to the
mechanism they claim occurs with asbestos and
MSU crystals.25 Hornung et al. recently proposed
that crystal structures such as silica, MSU and alum
can destabilize lysosomes and cause the release of
cathepsin-B into the cytosol, and that this activates
the NLRP3 inflammasome.35 However, by using cells
from cathepsin-B-deficient mice, Dostert et al.
showed that this was not the case for sHZ-induced
IL1β responses. In turn, Tiemi-Shio et al. suggested
that cathepsin-B is activated during sHZ stimulation,
but that lysosomal damage does not occur.26 They
also showed that sHZ activates SykLyn-kinase-
mediated intracellular signaling pathways upstream
of NLRP3 or ASC, indicating the indirect activation of
NLRP3 and the existence of other hemozoin recep-
tor(s) such as Dectin1, TREM family members,
Siglec or DAP12.26 Accordingly, PI3-kinases, which
are downstream of Syk, are also involved in the regu-
lation of hemozoin-induced IL1β production. Of note,
PI3 kinases are the main regulators of CpG DNA (a
known TLR9 ligand)-induced activation.36 Currently,
it is not clear why such different signaling mecha-
nisms have been proposed by different groups.
ADAPTIVE IMMUNE RESPONSES TO
HEMOZOIN: A NOVEL ADJUVANT
Successful vaccines contain an adjuvant component
that triggers innate immune system activation for op-
timal immunogenicity.37,38 We recently found that
whole malaria parasite vaccines using P. falciparum
(Pf)-crude extracts derived from in vitro blood-stage
cultures contain a “built-in” adjuvant, which is medi-
ated by TLR9.13 Careful analysis of the components in
the Pf-crude extract that may be responsible for this
TLR9-dependent adjuvant effect showed that Plasmo-
dium DNA is not involved. Another candidate compo-
nent could be hemozoin, as reported earlier.39 In sup-
port of this idea, synthetic hemozoin shows a potent
adjuvant effect with several model antigens, as well as
malaria antigens, when immunized subcutaneously,
intraperitoneally or intranasally to mice. Antigen-
specific IgG responses (mainly IgG1 followed by
IgG2b and IgG2c) were increased by sHZ. Substan-
tial amounts of IL-13 and IL-5 were produced by
spleen cells, but no IFNγ or IL17 was detected.13
These data suggest that hemozoin is the “built-in”
adjuvant for whole-parasite vaccination using the P.
falciparum (Pf)-crude extract. On the other hand, one
can still argue that there may be a possibility that the
Pf-crude extract may contain a non-DNA, non-
hemozoin TLR9 ligand. It seems technically very diffi-
cult to remove hemozoin from the Pf-crude extract,
or to prove that hemozoin is an essential TLR9 ligand
within the extract. However, as mentioned above, we
have shown that both natural and synthetic hemozoin
specifically bind to TLR9 and change its conforma-
tion, thereby confirming that hemozoin fulfills the
definition of a TLR9 ligand.13
In contrast to the TLR9-dependency of the adjuvant
effect of Pf-crude extract vaccination, the adjuvant ef-
fect of sHZ was not mediated by TLR9, but required
MyD88.13 We postulated that NLRP3 might be in-
volved, as hemozoin-induced IL-1β secretion in
macrophages is mediated by the inflammasome
NLRP3IL-1β pathway.25-27,33 However, in vivo
NLRP3 deficiency does not alter the adjuvant effect of
sHZ. Thus, more studies are required to elucidate the
mechanism by which hemozoin exerts its adjuvant
activity in the innate immune response. This will in-
volve detailed examination of whether TLR9 and
NLRP3 have different roles to play, or whether other
molecules are involved.40
Alum (a well known particulate adjuvant), along
with the type of cells recruited in response to alum
and their role in its adjuvant effect, have been ana-
lyzed extensively.41 Neutrophils, monocytes, macro-
phages and eosinophils are recruited into the injec-
tion site after immunization with alum, but are not
necessary for its adjuvant effects. Similarly, we found
that synthetic hemozoin can recruit neutrophils to the
peritoneum, and that this neutrophil recruitment is
regulated entirely by MyD88, and not by TLR9 or
NLRP3.13 Although these results contradict those of
others who propose NLRP3- or ASC-dependent neu-
trophil recruitment into the peritoneum of mice after
sHZ injection,25-27 our data nevertheless suggest that
the adjuvant effect of hemozoin is closely correlated
with neutrophil recruitment. Further studies are
needed to understand this correlation, although the
reason for the different results published by many
groups is unclear.
Nonetheless, we want to stress an important point
needed to understand the adjuvant effect of synthetic
hemozoin. Although the chemical properties of syn-
thetic hemozoin produced using any of the several
different purification protocols are similar, the vari-
able sizes and appearance of the crystals may have a
profound effect on their immunogenicity.13,15 Syn-
thetic hemozoin crystals between 50 nm and 200 nm
have optimal adjuvant effects when compared with
larger sHZ molecules (2-20 μm; Table 1). Given the
fact that the size of other particle adjuvants taken up
by antigen-presenting cells via receptor-mediated en-
docytosis is around 50-200 nm, it is reasonable to find
‘optimal size’ for the adjuvant effect of synthetic
hemozin crystals and their signaling pathways.42,43 It
is conceivable that cellular uptake and internalization
(i.e. modification of the integrity of the phagosomal
andor endosomal membrane) of both natural and
synthetic hemozoin may differ due to their different
crystal sizes. Clearly, further investigation is needed
Hemozoin Is an Adjuvant from Malaria Parasites
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Fig. 4 Hemozoin is a potent adjuvant in dog alergy vaccines. (a) Successful sensitization of Beagle dogs with the Derf2 
house dust mite alergen. Dogs were sensitized intradermaly three times with a Derf2/alum mixture, before a skin test was car
ried out. Saline was used as negative control, while histamine was used as a positive control. Serum IgE responses corelated 
with the skin test reaction. (b) Immunization and sensitization protocol. (c) IgG2 and IgG1 responses 2 weeks after the booster 
immunizations(*p < 0.05). (d) IgE responses after sensitization with antigen(**p < 0.01). (b) and (d) were reproduced from Co
ban et al. under copyright permission.13
a) Beagle dog house dust mite allergen (Derf2) sensitization
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to uncover possible receptors(s), or to understand
the co-ordination between receptors and signaling
pathways in response to hemozoin. Currently, studies
are underway to examine whether the different sizes
of synthetic and natural hemozoin crystals require
distinct delivery systems have different mechanisms
of interaction with innate immune cells and their re-
ceptors.
In fact, the physiological relevance of TLRs and
NLRs during adaptive immune responses to malaria
infections, and the role of hemozoin in vivo, is the
subject of much debate. Some have suggested, by us-
ing different mouse models and various Plasmodium
species, that the role of NLRP3 in the pathogenesis of
malaria infections is limited.25-27,33 The involvement of
TLR9 during malaria infection in both in human44-47
and mouse studies48-52 has gained much attention re-
cently, with some reports suggesting that TLR9 has
no role to play.53-55
HEMOZOIN IS A POTENT ADJUVANT
AGAINST DOG ALLERGY
The discovery and evaluation of new adjuvants for
use in humans is a time and energy consuming proc-
ess. The final product must be safe, potent and cheap
to distribute to those who need it most. The evalu-
ation of new products in higher animals may lead to
the use of some of these products as pet vaccines. So,
can synthetic hemozoin be a good adjuvant in higher
animals or, ultimately, in humans? To address this
question, the adjuvant effects of synthetic hemozoin
were studied in a dog allergy model. Atopic dermati-
tis is a common allergic skin disorder in both dogs
and humans, with closely related symptoms and im-
munological mechanisms.56 It is associated with the
production of high levels of IgE antibodies against al-
lergens such as Dermatophagoides farinae, the house
dust mite. Beagle dogs sensitized by intradermal in-
Coban C et al.
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jections of Derf2 (one of the major allergens of house
dust mites57) and alum develop allergic skin reactions
that can be evaluated by a skin test (Fig. 4a). This
skin test reaction has been found to be well corre-
lated with serum IgE responses to given allergens.58
Using this model, Beagle dogs were immunized with
Derf2, together with alum and synthetic hemozoin,
and boosted 2 weeks later (see Fig. 4b for immuniza-
tion and sensitization protocol). After the immuniza-
tions, significantly elevated levels of IgG2, but not
IgG1, antibodies were found in the sHZ-treated
group, resembling Th1-like immune responses in
dogs (Fig. 4c).59 Finally, immunized dogs were sensi-
tized with the Derf2 allergen and the Derf2-specific
IgE responses were analyzed. The Derf2-specific IgE
responses were significantly reduced in the sHZ co-
treated dogs after allergen sensitization (Fig. 4d).
These data suggested that, although it acts like a
Th2-dominant adjuvant in a murine model, sHZ may
serve as a potent Th1-like adjuvant in a canine model.
Finally, canine allergies to house dust mites closely
resembles those in humans, so these experiments
warrant further attention, at least in terms of prevent-
ing allergic reactions to house dust mites in both
dogs and humans.
CONCLUSIONS
Recent studies have improved our understanding of
the mechanism by which hemozoin crystals may acti-
vate the innate immune system. DNA-free hemozoin,
both in natural and synthetic form, can directly bind
to and induce conformational changes in TLR9, lead-
ing to the activation of innate immune responses.
Both forms of hemozoin possess adjuvant properties,
but use different innate immune receptors. These
studies suggest that one should be careful when pro-
ducing synthetic hemozoin, since the adjuvant effect
depends on its method of synthesis and particle size.
Studies are underway to make a GMP-lot synthetic
hemozoin as a safe and cheap adjuvant for the univer-
sal use in both animal and human vaccines.
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